AU2020240069B2 - Compositions and methods to treat gastrointestinal diseases and disorders - Google Patents

Compositions and methods to treat gastrointestinal diseases and disorders

Info

Publication number
AU2020240069B2
AU2020240069B2 AU2020240069A AU2020240069A AU2020240069B2 AU 2020240069 B2 AU2020240069 B2 AU 2020240069B2 AU 2020240069 A AU2020240069 A AU 2020240069A AU 2020240069 A AU2020240069 A AU 2020240069A AU 2020240069 B2 AU2020240069 B2 AU 2020240069B2
Authority
AU
Australia
Prior art keywords
rifaximin
nac
mucolytic agent
dtt
ibs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020240069A
Other languages
English (en)
Other versions
AU2020240069A1 (en
Inventor
Gabriela Guimaraes Sousa LEITE
Ruchi Mathur
Walter Morales
Mark Pimentel
Ali REZAIE
Stacy WEITSMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU2020240069A1 publication Critical patent/AU2020240069A1/en
Application granted granted Critical
Publication of AU2020240069B2 publication Critical patent/AU2020240069B2/en
Priority to AU2025271108A priority Critical patent/AU2025271108A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020240069A 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders Active AU2020240069B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025271108A AU2025271108A1 (en) 2019-03-18 2025-11-20 Compositions and methods to treat gastrointestinal diseases and disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819986P 2019-03-18 2019-03-18
US62/819,986 2019-03-18
PCT/US2020/023396 WO2020191076A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025271108A Division AU2025271108A1 (en) 2019-03-18 2025-11-20 Compositions and methods to treat gastrointestinal diseases and disorders

Publications (2)

Publication Number Publication Date
AU2020240069A1 AU2020240069A1 (en) 2021-10-28
AU2020240069B2 true AU2020240069B2 (en) 2025-08-28

Family

ID=72520533

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020240069A Active AU2020240069B2 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders
AU2025271108A Pending AU2025271108A1 (en) 2019-03-18 2025-11-20 Compositions and methods to treat gastrointestinal diseases and disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025271108A Pending AU2025271108A1 (en) 2019-03-18 2025-11-20 Compositions and methods to treat gastrointestinal diseases and disorders

Country Status (7)

Country Link
US (1) US20230038019A1 (https=)
EP (1) EP3941461A4 (https=)
JP (1) JP2022526495A (https=)
CN (1) CN113645968A (https=)
AU (2) AU2020240069B2 (https=)
CA (2) CA3132400A1 (https=)
WO (1) WO2020191076A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205650A1 (en) * 2022-04-20 2023-10-26 Cedars-Sinai Medical Center Methods of diagnosing ibs-d and selection of ibs-d treatment
US20250275950A1 (en) * 2022-05-19 2025-09-04 Cedars-Sinai Medical Center Rifaximin and n-acetyl cysteine formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1235529A (en) * 1968-12-02 1971-06-16 Calbiochem Composition for mucolysis
TWI236905B (en) * 1997-10-28 2005-08-01 Jens Ponikau Pharmaceutical composition for treating and preventing inflammation of mucosal tissue
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20060264409A1 (en) * 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
WO2005118860A2 (en) * 2004-04-09 2005-12-15 General Hospital Corporation Compositions and methods related to an intestinal inflammation and uses therefor
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
US20120283411A9 (en) * 2006-06-29 2012-11-08 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0823472D0 (en) * 2008-12-23 2009-01-28 Photocure Asa Product
JP2013518895A (ja) * 2010-02-03 2013-05-23 マイクロビオン コーポレーション 細菌バイオフィルムの処置および他の使用をはじめとする、生体医学的使用のための消毒薬としてのビスマス−チオール
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
WO2014070769A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
US20160158262A1 (en) * 2013-07-26 2016-06-09 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome
SG11201700621XA (en) * 2014-07-25 2017-02-27 Agency Science Tech & Res Antibiotic compositions for treating bacterial infections
DK3288554T3 (da) * 2015-04-30 2022-11-14 Probiotical Spa Anvendelse af antibiotika med specifikke terapeutiske aktiviteter kombineret med samtidig anvendelse af lactobacilli og/eller bifidobakterier med en ikke-overførbar antibiotisk resistens med den samme terapeutiske indikation
KR20190116320A (ko) * 2017-02-07 2019-10-14 에스티씨. 유엔엠 오래 지속되는 자가 포식 유도를 위한 동위 원소 강화 암브록솔

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Khameneh, B.; et al. Microb. Pathog. 2016, 93, 83-87. DOI: https://doi.org/10.1016/j.micpath.2015.11.006 *
Wang, Q.; et al., "Protective effects of N-acetylcysteine on acetic acid-induced colitis in a porcine model", BMC Gastroenterology 2013, 13, no. 133, 11 pages. DOI: https://doi.org/10.1186/1471-230X-13-133 *

Also Published As

Publication number Publication date
EP3941461A4 (en) 2022-12-14
AU2020240069A1 (en) 2021-10-28
CA3293273A1 (en) 2026-03-02
AU2025271108A1 (en) 2025-12-18
EP3941461A1 (en) 2022-01-26
US20230038019A1 (en) 2023-02-09
CA3132400A1 (en) 2020-09-24
JP2022526495A (ja) 2022-05-25
WO2020191076A1 (en) 2020-09-24
CN113645968A (zh) 2021-11-12

Similar Documents

Publication Publication Date Title
AU2025271108A1 (en) Compositions and methods to treat gastrointestinal diseases and disorders
Rasmussen et al. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis
Tryba Risk of acute stress bleeding and nosocomial pneumonia in ventilated intensive care unit patients: sucralfate versus antacids
US20040067223A1 (en) Probiotic compositions for the treatment of inflammatory bowel disease
US11154589B2 (en) Antimicrobial composition combinations comprising star shaped peptide polymers
EP2485742A1 (en) Antibiotic formulations providing reduced gastrointentestinal side effects
US20210338749A1 (en) Methods of treatment of inflammatory conditions and associated infections
US20110294726A1 (en) Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
EP2987503A1 (en) Methods and reagents for prevention and/or treatment of infection
US3567821A (en) Medicament for the affections of mucous membranes
WO2016120787A1 (en) Oral n-acetylcysteine in the treatment of upper respiratory tract infections and symptoms
US20260076993A1 (en) Composition for the treatment of lesions of the respiratory system
US20190224150A1 (en) Method of treatment and prevention of bacterial vaginosis
HK40064209A (en) Compositions and methods to treat gastrointestinal diseases and disorders
CN102470141A (zh) 作为用于抗微生物肽产生能力的滋补剂的甘草酸
US20030073625A1 (en) Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides
RU2297835C1 (ru) Препарат для лечения неинфекционных воспалительных болезней кишечника
RU2810419C1 (ru) Способ лечения хронического пародонтита
JP7705844B2 (ja) クロストリディオイデス ディフィシル菌増殖抑制剤
RU2751809C1 (ru) Способ лечения пародонтита
RU2325166C1 (ru) Фармацевтическая композиция антибиотиков и лактулозы для профилактики энтеральных дисбиозов в процессе антибиотикотерапии
Zhu et al. A Case Report of Persistent Acinetobacter baumannii Bloodstream Infection
Di Stefano et al. Efficacy of the treatment of infectious diarrhoea with non-absorbable rifamycin SV formulated as MMX modified release tablet vs. rifaximin
EP4561550A1 (en) Therapeutic effect of molecules derived from probiotic milk-based fermentation microbial consortium ("kefir") on wounds healing
Wilson et al. Comparison of the Effectiveness of Oral and Intravenous Antibiotics for the Treatment of Acute Sinusitis in Children at Skopje Hospital, Macedonia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)